$VRSK

Mann Elizabeth sold $72K of VRSK

Mann Elizabeth (Chief Financial Officer) sold 400 shares of Verisk Analytics, Inc. (VRSK) at $179.54 on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mann Elizabeth
Published Jun 16, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VRSK
Neutral
high confidence
Mentioned
$VRSK
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VRSKNeutralLow
01

Why it matters

This provides incremental transparency on insider activity but does not include new operational, financial, or regulatory information that would typically drive repricing.

02

Market read

A routine CFO 10b5-1 sale is unlikely to materially change valuation expectations, but it can be used as a minor sentiment datapoint.

03

What to watch

Traders may over-weight small insider sales; the key differentiator is the pre-arranged 10b5-1 designation, which reduces interpretive value.

Relevance 2/10Novelty 5/10Timing: Filed 2026-06-16; sale executed 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Verisk Analytics, reporting a CFO sale executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$VRSKNeutralHigh confidence
Context

Verisk CFO Elizabeth Mann sold 400 shares on 2026-06-15 under a pre-arranged 10b5-1 plan, worth about $71.8K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and small dollar value relative to company size.

Market effects

No sector read-across; this is company-specific ownership-change disclosure.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish fundamentals.

Key entities

  • Verisk Analytics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Mann Elizabeth

    CFO who sold shares; transaction details are reported on SEC Form 4.

  • Rule 10b5-1 plan

    Indicates the sale was pre-arranged, generally lowering interpretive signal.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VRSKMed

VRSK Maintained by Barclays -- Price Target Lowered to $225

Barclays maintained an Overweight rating on Verisk Analytics (VRSK) but lowered its price target from $275 to $225. The company's stock is trading at $179.17, which GuruFocus estimates is 44.4% undervalued. Verisk has a GF Score of 78/100, indicating strong profitability and growth, but lower momentum. Insider activity shows significant selling, with $2.55 million in sales over the past three months.

$VRSKMed

Is Verisk’s Q2 Beat, Buyback and AI Push Altering The Investment Case For Verisk Analytics (VRSK)?

Verisk Analytics (VRSK) reported Q2 2026 earnings and revenue above estimates, reaffirmed its 2026 outlook, and announced a $200M share repurchase. The company emphasized growth in AI and data analytics for insurance clients. Verisk projects $3.8B in revenue and $1.3B in earnings by 2029, with a 24% upside to its current price. The company's high debt levels and interest expenses remain key risks.

$VRSKMedAI 8/10

Verisk (VRSK) Down 4.7% Since Last Earnings Report: Can It Rebound?

Verisk (VRSK) shares fell 4.7% since its last earnings report. Q2 2026 earnings beat estimates at $1.98 per share, up 5.3% YoY. Revenue rose 4.3% to $806.3M. Underwriting and claims revenues increased 3.5% and 6.3% respectively. EBITDA grew 4.2% but net income declined 9.8% due to higher taxes and interest. The company maintained 2026 guidance and approved a dividend. Estimates have trended downward, with a Zacks Rank #3 (Hold).

$VRSKMedAI 8/10

Verisk Analytics v. AccuLynx: Sorry, You Actually DO Have To Comply With That Second Request

The Delaware Court of Chancery ordered Verisk Analytics to continue pursuing FTC clearance for its $2.35 billion acquisition of AccuLynx, despite Verisk's attempt to terminate the deal. The court ruled that Verisk's termination was invalid due to its willful conduct in ending negotiations with a competitor, ServiceTitan. Verisk must now comply with a costly Second Request process, which typically takes many months to complete. The court's decision is notable as it is the first to compel a buyer